Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539867 | 0.77 | AR (0.38) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL22423659 | 0.75 | CREBBP (0.40) | MAPTPOLBMEN1KMT2A | |
| SCHEMBL15129545 | 0.69 | BACE1 (0.39) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL15129747 | 0.69 | LMNA (0.35) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL31606046 | 0.67 | MAPT (0.40) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL6770931 | 0.67 | PGR (0.56) | LMNAPKM | |
| SCHEMBL1696201 | 0.64 | PGR (0.55) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL26922538 | 0.64 | BRD4 (0.45) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL16566161 | 0.64 | LMNA (0.36) | MAPTTP53POLBLMNAPKM | |
| SCHEMBL5499896 | 0.63 | LMNA (0.48) | MAPTTP53POLBLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835744-B2 | For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors | WYETH | 2004-12-28 | — | — | US | disclosed |
| EP-1175397-B1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | WYETH CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030008909-A1 | 3,3-substituted indoline derivatives | WYETH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6503939-B2 | That are antagonists of the progesterone receptor, in a female contraceptive kit | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-6417214-B1 | COMPOUNDS AS CONTRACEPTIVES | WYETH | 2002-07-09 | — | — | US | disclosed |
| CN-1349500-A | 3,3-substituted indoline derivatives | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1349417-A | Contraceptive compositions containing 3,3-substituted indoline derivatives and use thereof | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-20020035099-A1 | Combination regimens using 3,3-substituted indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1175397-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173211-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6329416-B1 | ADMINISTERING TO FEMALE OF CHILD BEARING AGE FOR 28 CONSECUTIVE DAYS: FIRST PHASE DOSAGE OF PROGESTATIONAL AGENT; SECOND PHASE OF ANTIPROGESIN COMPOUND, AND THIRD PHASE OF PLACEBO FOR CONTRACEPTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | disclosed |
| WO-2000066554-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066166-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008909-A1 | 3,3-substituted indoline derivatives | NR3C2, PGR, HTR3C | MAPT 3400/4885TP53 2279/4885POLB 4014/4885 |
| US-20020035099-A1 | Combination regimens using 3,3-substituted indoline derivatives | MC2R, PRLHR, MC5R | MAPT 4624/4885TP53 1293/4885POLB 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.